Why Diagnose Pulmonary Hypertension Early

Infographic: Why Early Diagnosis Matters
Download & share the campaign infographic: Why Early Diagnosis Matters
  • Pulmonary hypertension is a serious, debilitating, and often fatal progressive condition where the blood pressure in the lungs rises to dangerously high levels, ultimately resulting in right heart failure.

  • Without treatment, the median survival rate of patients with pulmonary hypertension is approximately 2.8 years.

  • Proper treatment has been found to extend life and improve quality of life, however early intervention remains the key to maximizing treatment efficacy and patient outcomes.

When an accurate PH diagnosis accompanied by appropriate treatment is achieved early in the disease progression (functional classes I & II), patients report fewer limitations and greater quality of life. For many this means maintaining the ability to work and continuing to enjoy family and social activities, as well as hobbies. Unfortunately, the REVEAL Registry shows that patients displaying milder impairment are among the groups experiencing the greatest diagnostic delays. Through the Early Diagnosis Campaign, PHA is working to change that.

Sources: Delay in Recognition of Pulmonary Arterial Hypertension: Factors Identified From the REVEAL Registry (PDF), Lynette M. Brown, MD, PhD, FCCP, et al (CHEST, 2011); PHA International White Paper, Pulmonary Arterial Hypertension: Recommendations for Improving Patient Outcomes (2011)

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

© 2015 Pulmonary Hypertension Association. All Rights Reserved.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy   Terms of Use    Provide Feedback & Report Bugs


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.